Ken Sikaris
Overview
Explore the profile of Ken Sikaris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
968
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Koerbin G, Sikaris K, Jones G, Flatman R, Tate J
Clin Chem Lab Med
. 2018 Jan;
57(1):38-41.
PMID: 29305566
The Australasian Association of Clinical Biochemists (AACB) has over the past 5 years been actively working to achieve harmonized reference intervals (RIs) for common clinical chemistry analytes using an evidence-based...
12.
Ooi G, Earnest A, Doyle L, Laurie C, Wentworth J, Sikaris K, et al.
Obes Surg
. 2017 Nov;
28(5):1351-1362.
PMID: 29159554
Introduction: Dyslipidemia affects up to 75% of morbidly obese individuals and is a key driver of cardiovascular disease. Weight loss is an established strategy to improve metabolic risk, including dyslipidemia....
13.
Trambas C, Lu Z, Yen T, Sikaris K
Ann Clin Biochem
. 2017 Sep;
55(2):205-215.
PMID: 28875734
Background Biotin interference is a significant problem to which at-risk laboratories must now be attuned. We sought to systematically characterize the nature of this interference in Roche immunoassays. Methods Known...
14.
Badrick T, Gay S, Mackay M, Sikaris K
Clin Chem Lab Med
. 2017 Aug;
56(2):264-272.
PMID: 28771429
Background: The determination of reliable, practical Quality Indicators (QIs) from presentation of the patient with a pathology request form through to the clinician receiving the report (the Total Testing Process...
15.
Trambas C, Lu Z, Yen T, Sikaris K
Ann Clin Biochem
. 2017 Apr;
55(2):216-226.
PMID: 28406314
Background Biotin interference in streptavidin-based immunoassays causes widespread analytical distortions that may lead to clinical confusion, inappropriate patient management and, ultimately, adverse events. Its prevalence has increased recently due to...
16.
Shah S, Chiang C, Sikaris K, Lu Z, Bui M, Zebaze R, et al.
J Clin Endocrinol Metab
. 2017 Apr;
102(7):2321-2328.
PMID: 28379394
Context: Vitamin D "insufficiency" and "deficiency" are defined as serum 25-hydroxyvitamin D [25(OH)D] levels <75 and <30 nmol/L, respectively. We aimed to determine whether these values signal hypocalcemia and hypophosphatemia,...
17.
Badrick T, Barden H, Callen S, Dimeski G, Gay S, Graham P, et al.
Clin Biochem Rev
. 2017 Feb;
37(4):140-142.
PMID: 28167843
No abstract available.
18.
Ooi G, Burton P, Doyle L, Wentworth J, Bhathal P, Sikaris K, et al.
Obes Surg
. 2016 Dec;
27(6):1533-1542.
PMID: 27966066
Objectives: Nonalcoholic fatty liver disease (NAFLD) affects over 80% of obese patients and is fueled by the metabolic syndrome. Weight loss is strongly advocated as a central treatment for NAFLD...
19.
Ooi G, Burton P, Doyle L, Wentworth J, Bhathal P, Sikaris K, et al.
Obes Surg
. 2016 May;
27(1):115-125.
PMID: 27220852
Background: Obesity and its related comorbidities are significant risk factors for nonalcoholic fatty liver disease (NAFLD). Liver fibrosis is the major determinant of long-term outcomes in NAFLD. A non-invasive tool...
20.
Hadlow N, Sikaris K
Clin Biochem Rev
. 2016 Feb;
36(4):127-32.
PMID: 26900191
No abstract available.